DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy.
Joana F WoodsSimiso SokhelaGodspower AkpomiemieBronwyn BoschKarlien MöllerEsther BhaskarChelsea KrugerNcomeka ManentsaNoxolo TomPhiladelphia MacholoNomathemba ChandiwanaAndrew HillMichelle MoorhouseWillem Daniel Francois VenterPublished in: HIV medicine (2024)
Our findings suggest that a switch to doravirine from efavirenz or dolutegravir is safe and effective in Black women, with significant improvement in lipid profiles, but does not arrest progressive weight gain.